Modality
mAb
MOA
CD3xCD20
Target
BCMA
Pathway
PI3K/AKT
Endometrial Ca
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
~Jan 2018
→ ~Apr 2019
Phase 3
Jul 2019
→ Jul 2029
Phase 3Current
NCT07005953
668 pts·Endometrial Ca
2019-07→2029-07·Not yet recruiting
NCT05154006
1,568 pts·Endometrial Ca
2023-08→2025-04·Recruiting
NCT05285642
2,343 pts·Endometrial Ca
2024-07→2026-11·Active
+1 more trial
6,277 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-04-1412mo agoPh3 Readout· Endometrial Ca
2026-11-178mo awayPh3 Readout· Endometrial Ca
2029-07-133.3y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P3
Not yet…
P3
Not yet…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2025-04-14 · 12mo ago
Endometrial Ca
Ph3 Readout
2026-11-17 · 8mo away
Endometrial Ca
Ph3 Readout
2029-07-13 · 3.3y away
Endometrial Ca
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07005953 | Phase 3 | Endometrial Ca | Not yet recr... | 668 | Biomarker |
| NCT05154006 | Phase 3 | Endometrial Ca | Recruiting | 1568 | NT-proBNP |
| NCT05285642 | Phase 3 | Endometrial Ca | Active | 2343 | PASI75 |
| NCT04807236 | Phase 3 | Endometrial Ca | Not yet recr... | 1698 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |